Jan 09, 2023 / 07:15PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat with Chris Viehbacher, who joined Biogen a little bit less than 2 months ago as CEO. So Chris, Happy New Year, and thanks for joining us today.
Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director
Thanks. Happy New Year to you.
Questions and Answers:
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior AnalystSo maybe just to kick off. It seems like you're joining a company that's kind of at a crossroads. So you've got, obviously, a very exciting new launch in the Alzheimer's side. We've got a large pipeline, but one I think is viewed as kind of high-risk high reward, and we've got a base business that's got some LOE pressures. So can you talk about the key challenges that you see facing Biogen right now and how your kind of plan to prioritize these as you think about your